A multicenter randomized, double-blind, controlled study of NGX-4010 [capsaicin] for the treatment of postherpetic neuralgia

Trial Profile

A multicenter randomized, double-blind, controlled study of NGX-4010 [capsaicin] for the treatment of postherpetic neuralgia

Completed
Phase of Trial: Phase III

Latest Information Update: 01 Jan 2011

At a glance

  • Drugs Capsaicin (Primary)
  • Indications Neuropathic pain; Postherpetic neuralgia
  • Focus Therapeutic Use
  • Sponsors NeurogesX
  • Most Recent Events

    • 19 Dec 2008 Based on the results of this trial and one other, the FDA has accepted a NDA for review, reported by NeurogenesX. The brand name Qutenza is awaiting approval.
    • 04 Mar 2008 Status changed from in progress to completed.
    • 18 Apr 2007 Status changed from recruiting to in progress
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top